Processa Pharmaceuticals (PCSA) Share-based Compensation (2012 - 2026)
Processa Pharmaceuticals' (PCSA) quarterly Share-based Compensation came in at $320.0 in Q1 2026, down 99.86% YoY from $227711.0 in Q1 2025, and down 99.74% on a QoQ basis from $123544.0 in Q4 2025.
Processa Pharmaceuticals (PCSA) Share-based Compensation (2012 - 2026) Analysis & Trends
Processa Pharmaceuticals (PCSA) has 14 years of Share-based Compensation data on file, last reported at $320.0 in Q1 2026.
- Quarterly Share-based Compensation fell 99.86% year-over-year to $320.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $554826.0 (down 19.54% YoY) and the FY2025 annual result came in at $857550.0, up 36.22% from the prior year.
- Share-based Compensation declined to $320.0 in Q1 2026, from $123544.0 in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $3.2 million in Q3 2022 to a low of $320.0 in Q1 2026.
- A 5-year average of $682785.9 and a median of $185447.0 in 2024 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2022 — Share-based Compensation jumped 188.43% — and 2026, when it slumped 99.86%.
- Tracing PCSA's Share-based Compensation over 5 years: stood at $2.8 million in 2022, then sank by 94.85% to $142894.0 in 2023, then grew by 8.51% to $155048.0 in 2024, then fell by 20.32% to $123544.0 in 2025, then sank by 99.74% to $320.0 in 2026.
- The last three Share-based Compensation figures came in at $320.0 (Q1 2026), $123544.0 (Q4 2025), and $108000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 86.63 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 41.25 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 28.05 Mn |
| 10 | Processa Pharmaceuticals | 5.93 Mn | 5.93 Mn | - | 92,105.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 320.00 |
| Mar 31, 2026 | 320.00 |
| Dec 31, 2025 | 123,544.00 |
| Dec 31, 2025 | 123,544.00 |
| Sep 30, 2025 | 108,000.00 |
| Sep 30, 2025 | 108,000.00 |
| Jun 30, 2025 | 203,251.00 |
| Jun 30, 2025 | 203,251.00 |
| Mar 31, 2025 | 227,711.00 |
| Mar 31, 2025 | 227,711.00 |
| Dec 31, 2024 | 155,048.00 |
| Dec 31, 2024 | 155,048.00 |
| Sep 30, 2024 | 154,191.00 |
| Sep 30, 2024 | 154,191.00 |
| Jun 30, 2024 | 152,632.00 |
| Jun 30, 2024 | 152,632.00 |
| Mar 31, 2024 | 167,643.00 |
| Mar 31, 2024 | 167,643.00 |
| Sep 30, 2023 | 142,894.00 |
| Sep 30, 2023 | 142,894.00 |